glp-1 anesthesia guidelines Glucagon-Like Peptide-1 Receptor Agonists in Perioperative Care Updated Guidelines on GLP-1 Agonists

This led Omada and Express Scripts to theorize that with behavior change support through the Omada for Prevention program, individuals taking GLP-1s for weight loss would see greater success

Several studies have estimated the costeffectiveness of GLP1s for obesity from a healthcare perspective, considering costs for screening and treatment against savings from improved weight and health outcomes and corresponding longterm reductions in healthcare utilization, including downstream accumulated health benefits

Here we elected to underscore some of the many instances where sex was either not provided, not disaggregated, or not appropriately analyzed to highlight the many missed opportunities to understand sex differences in this system

Studies have shown that adipokine levels are highly associated with insulin resistance

Medical supervision is critical for safety and effectiveness

Pemvidutide and survodutide are both GLP-1/glucagon dual agonists being developed for obesity and MASH, but survodutide is further ahead in clinical development with more advanced Phase 3 programs, higher-tier regulatory designations (Breakthrough Therapy vs Fast Track), and greater weight loss in Phase 2 (18.7% vs 15.6%)